Joana Goncalves
CIK 1756991 · Chief Medical Officer · last filed 2026-07-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.28M
Companies
2
Total Filings
48
Lifetime Open-Market Net
-$3.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORKA | Chief Medical Officer | 36,218 | $90.45 | $3.28M | -$3.03M | 10 | 2026-07-15 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | CHIEF MEDICAL OFFICER | 1,482 | $15.96 | $23.7K | -$942.1K | 35 | 2024-04-09 |
Recent Filings · Page 2 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-19 | ORKA | Notice (144) | −28,000 | -$788.2K | EDGAR |
| 2025-12-19 | ORKA | Mixed | — | -$163.1K | EDGAR |
| 2025-01-24 | ORKA | Grant (A) | — | $0 | EDGAR |
| 2024-04-09 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −2,753 | -$2.3K | EDGAR |
| 2024-03-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −3,293 | -$2.9K | EDGAR |
| 2024-02-12 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −7,770 | -$4.1K | EDGAR |
| 2024-02-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Grant (A) | +13,500 | $0 | EDGAR |
| 2023-06-27 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −2,723 | -$9.6K | EDGAR |
| 2023-04-06 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −2,481 | -$12.2K | EDGAR |
| 2023-03-07 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −6,221 | -$60.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.